Trial Profile

A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 13 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WVT 078 (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man
Sponsors Novartis Pharmaceuticals

Most Recent Events

09 Jan 2025 Status changed from active, no longer recruiting to discontinued ,The decision was made for business reasons and was not based on any safety or tolerability concerns
14 Mar 2024 Planned End Date changed from 16 Sep 2024 to 2 Dec 2024.
14 Mar 2024 Planned primary completion date changed from 16 Sep 2024 to 29 Nov 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com